Menu Search
Equities

OraSure Technologies Inc

EP3:MUN

OraSure Technologies Inc

Actions
  • Price (EUR)3.94
  • Today's Change-0.04 / -1.01%
  • Shares traded15.00
  • 1 Year change-32.07%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 16:45 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.

  • Revenue in USD (TTM)224.26m
  • Net income in USD11.37m
  • Incorporated2000
  • Employees638.00
  • Location
    OraSure Technologies Inc220 E First StBETHLEHEM 18015United StatesUSA
  • Phone+1 (503) 641-6115
  • Fax+1 (610) 882-1830
  • Websitehttps://www.orasure.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.